Post-Operative Cataract Surgery Inflammation Treatment Market Snapshot (2023 to 2033)

The global post-operative cataract surgery inflammation treatment market is slated to reach a valuation of USD 4.56 billion in 2023. According to Future Market Insights, the market is expected to grow at a 6.77% CAGR until 2033, valued at USD 8.78 billion.

Post-operative cataract surgeries are driven mainly by the aging population and the increased prevalence of ocular disorders resulting in higher demand for cataract surgery devices.

The increasing demand in the global cataract market is a replication of the growing elderly population, as people aged over 60 years frequently develop conditions in which eyes have reduced elasticity, and in turn, it affects normal functioning. This boosts market growth.

The rise in the number of cortical necrosis therapeutics being delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global cataracts market over a forecast period.

The huge expenditure associated with the treatment of cataracts surely hampers market growth. The high cost of cataract surgery, mainly in developing countries such as India, Brazil, South Africa, and China restrains the global market.

Attributes Details
Base year Market Value (2022) USD 4.045 billion
Projected Forecast Value (2023) USD 4.56 billion
Projected Forecast Value (2033) USD 8.78 billion
Growth rate (2023 to 2033) 6.77%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Post-Operative Cataract Surgery Inflammation Treatment Market Historical Period 2018 To 2022 Demand Analysis Vs. Forecast 2023

The global post-operative cataract surgery inflammation treatment grew at a CAGR of 6.45% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.

Historically, the choice of intraocular lenses (IOLs) is a field that has seen great improvement. Optical biometers were then available and had become more affordable, providing more accurate measurements than those provided by ultrasonography, by reaching optimal accuracy even in dense and advanced cataracts.

Also, artificial intelligence was used for enhancing the precision of IOL calculations and personalized approaches for both patients and surgeons. Postoperative adjustment of IOL power had become available with the introduction of novel IOL technologies.

The progress in evaluating the anterior surface and the tear apparatus has shown that tear dysfunction can significantly affect surgical outcomes, including producing a less precise IOL calculation and a longer postoperative recovery.

But nowadays, the current study is the first to compare intracanalicular dexamethasone directly to topical steroids after cataract surgery. Importantly, the study showed that the safety and efficacy of the two approaches were similar.

The rates of breakthrough inflammation reported for both groups were similar to those reported by previous studies where more than half of the patients experiencing breakthrough inflammation admitted poor compliance or anxiety over administering drops.

Although, the investigators of the current study have noted that patients should be counseled on possible epiphora in the postoperative period where two of 24 patients have been experiencing canalicular obstruction with an intracanalicular dexamethasone ophthalmic insert.

Prominent Growth Drivers Influencing Post-Operative Cataract Surgery Inflammation Treatment Market

Rising prevalence of ophthalmic disorders & ocular pains

Ophthalmic disorders are the vital cause of major ocular and orbital pains in the eye. Ocular pain occurs over the surface of the eyes along with symptoms such as scratching, burning, or itching sensation.

This may be due to multiple reasons, including irritation from foreign objects, infection, or trauma. Eyelashes or pieces of dirt, smoke, dust, or some harsh eye cosmetics are the common causes leading to ocular pain, redness, and watery eyes.

The prevalence of ocular pain keeps showing a surge in growth as chemical industries and pollution around the world are growing. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface. Style and blepharitis lead to severe ocular pain as they cause eye and oil glands to be more sensitive around the area.

A rise in traumatic injuries

Traumatic head injury is one of the causes of such disorders as optic nerve disorders. A traumatic injury is a physical injury that occurs suddenly with a certain degree of severity. Trauma can be caused by a variety of external injuries.

The most common causes of traumatic injury include road accidents, sports injuries, and violence, among others which can lead to some serious eye disorders as well. The prevalence of such traumatic injuries is highly seen worldwide.

Hence, such traumatic injuries lead to optic nerve disorders, which are affecting the population in these years and it is increasing with the rising population. Therefore, a rise in traumatic injuries is expected to drive market growth.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Could Possibly Hinder Post-Operative Cataract Surgery Inflammation Treatment Market Demand?

High cost & risks associated with eye surgery & treatment

The cost of the various disorders treatment plays a major role in the market. The optic nerve disorders treatments are highly sophisticated, as the prevalence of such disorders is increasing; hence the need for such products has eventually raised, thereby raising the treatment cost, which can hinder the market growth in the coming years.

There are various methods for the treatment of optic neuritis disorder. Some of them are patients can take various medicines such as corticosteroids like methylprednisolone, prednisone, immunoglobulin, vitamin B12 shots, and various other surgeries. With these, there are some risks associated with it.

Therefore, for some of the population around the country, it is difficult for them to undergo such treatments due to the high cost. Hence, the high cost associated with ophthalmic disorders treatment is expected to restrain the market growth.

Lack of skilled professionals

The number of ophthalmologists in both emerging and industrialized countries is minor. However, projections are a little higher for developing countries. The number of ophthalmologists is cumulative but not as fast as the population of elderly patients aged 60 years or older who need to be amplified ophthalmologic care.

In most countries, the problem is that demographic changes do not match up with professional development. It is required to train eye care teams to meet the current number of ophthalmologists worldwide. The increased need for ophthalmologists globally also reflects an increase in the cases of diabetes.

Diabetic patients should get their eyes inspected every year. The increasing demand for ophthalmologists is directly proportional to the growing geriatric population since eye care is an integral part of healthcare. The access to care gaps can be met by combining factors, including more efficient practice structures, processes, and appropriate use of technology.

Region-wise Analysis

What Is the Outlook of The North American Post-Operative Cataract Surgery Inflammation Treatment Market?

Growth in the number of surgical procedures

The United States is expected to hold a major share of the market in North America. The major factors bolstering the market's growth are the growing number of surgical procedures, surge in awareness regarding postoperative pain management drugs, increasing number of product approvals, and rising focus on palliative care.

A research study titled "Comparison of Postoperative Pain Management Outcomes in the United States” was published stating that the American Pain Society Patient Outcome Questionnaire-Revised (APS-POQ-R) was completed by 244 patients in the United States with similar surgery sites. The Pain Management Index (PMI) was calculated on their first postoperative day.

Patients in the United States had a higher score on the APS-POQ "perception of pain management" subscale and a larger proportion of acceptable treatment, as assessed by the PMI.

Also, higher compliance with pain management recommendations has resulted in higher perceptions among patients. Such statistics are likely to increase the demand for postoperative pain management medications within the country, thereby boosting the market's growth.

Rise in the number of product approvals

Several market players are engaged in implementing strategic initiatives, thereby contributing to the market's growth.

In May 2021, Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform postsurgical pain management and recovery, reported the first-ever clinical data showing non-opioid pain relief lasting two weeks after a single administration and Heron.

Therapeutics, Inc., a commercial-stage biotechnology company focused on developing treatments to address some of the most important unmet patient needs, reported that the United States Food and Drug Administration (FDA) has approved ZYNRELEF (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after a bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which Type of Post-Operative Cataract Surgery Inflammation Drug Treatment Market is Most Prevalent?

Bromfenac drug gains the dominant market share

Bromfenac ophthalmic solution 0.09% is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction.

This is so because, the efficacy and safety of sodium bromfenac eye drop in the treatment of postoperative inflammation of cataract surgery were evaluated by the effective rate, symptom score, adverse reactions, incidence, recurrence rate, etc.

Which route of administration is expected to gain traction from 2023 to 2033?

Injections are expected to boost the market share

Intracameral dexamethasone injection in the treatment of cataract surgery-induced inflammation.

Topical ophthalmic drug delivery represents the most popular option among cataract surgeons due to its effectiveness and good safety profile in controlling inflammation after cataract surgery.

Start-up Scenario

  • The United Kingdom -based subsidiary of Japanese ophthalmology firm Santen Pharmaceutical has announced the launch of Ducressa in the UK and Ireland, a fixed-dose combination (FDC) of levofloxacin and dexamethasone for use after cataract surgery that also offers a modern and convenient seven-day therapeutic strategy to optimize post-surgery care. Levofloxacin is a proven broad-spectrum antibiotic and dexamethasone, a potent anti-inflammatory agent, the company noted.
  • Sun Pharmaceutical Industries has received approval from the US health regulator for its non-steroid drug BromSite used to treat inflammation and prevent pain in patients undergoing cataract surgery.

How Competitive is the Market for Post-Operative Cataract Surgery Inflammation Drug Treatment Market Most Prevalent?

Some of the prominent players in the post-operative cataract surgery inflammation drug treatment market are

  • Mallinckrodt Pharmaceuticals
  • Salix Pharmaceuticals
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • ASKA Pharmaceutical Co., Ltd.
  • Bausch Health
  • Johnson & Johnson Services, Inc.
  • Janssen Global Services
  • Takeda Pharmaceutical Company Limited
  • Merck & Co., Inc.

Some of the important developments of the key players in the market are

  • In October 2022, Regeneron Pharmaceuticals, Inc. announced the USA. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants. This development helps the organization in developing its brand image in the ophthalmology market, among others.
  • In May 2022, Reichert, Inc. launched its redesigned refractometers & analytical instruments website with a vastly improved user experience.

Report Scope

Report Attribute Details
Growth Rate CAGR of 6.77% from 2023 to 2033
Market value in 2023 USD 4.56 Billion
Market value in 2033 USD 8.78 Billion
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units USD Billion for Value and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered Drug class, Route of Administration, Distribution Channel, Region
Regions Covered

North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa

Key Countries Profiled United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC countries, South Africa, Israel
Key Companies Profiled Mallinckrodt Pharmaceuticals; Salix Pharmaceuticals; GlaxoSmithKline plc.; Pfizer Inc.; ASKA Pharmaceutical Co., Ltd.; Bausch Health; Johnson & Johnson Services, Inc.; Janssen Global Services; Takeda Pharmaceutical Company Limited; Merck & Co., Inc.
Customization Scope Available on Request

Key Segments Profiled in the Post-Operative Cataract Surgery Inflammation Drug Treatment Market

By Drug Class:

  • Bromfenac
  • Indomethacin
  • Dicofenac
  • Flurbiprofen
  • Nepafenac

By Route of Administration:

  • Oral
  • Injectable

By Distribution Channel:

  • Hospital pharmacy
  • Online Pharmacy
  • Retail pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is Current Market Valuation?

The market is estimated to secure a valuation of USD 4.56 billion in 2023.

How Big Will be the Market by 2033?

The market is estimated to reach USD 8.78 billion by 2033.

What is the Growth Potential of the Market?

Through 2033, the market is anticipated to expand at a 6.77% CAGR.

Which Route of Administration Segment to Lead the Market by 2023?

The market share for Injections segment is going to be the leading segment

Which Drug Class Segment to Lead the Market by 2023?

The bromfenac segment to be the leading segment in the market.

Table of Content
	1. Executive Summary
	2. Market Overview
	3. Market Background
	4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
	5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
		5.1. Bromfenac
		5.2. Indomethacin
		5.3. Diclofenac
		5.4. Flurbiprofen
		5.5. Nepafenac
	6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
		6.1. Oral
		6.2. Injectable
	7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
		7.1. Hospital Pharmacy
		7.2. Online Pharmacy
		7.3. Retail Pharmacy
	8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
		8.1. North America
		8.2. Latin America
		8.3. Europe
		8.4. South Asia
		8.5. East Asia
		8.6. Oceania
		8.7. MEA
	9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	16. Key Countries Market Analysis
	17. Market Structure Analysis
	18. Competition Analysis
		18.1. Mallinckrodt Pharmaceuticals
		18.2. Salix Pharmaceuticals
		18.3. GlaxoSmithKline plc.
		18.4. Pfizer Inc.
		18.5. ASKA Pharmaceutical Co., Ltd.
		18.6. Bausch Health
		18.7. Johnson & Johnson Services, Inc.
		18.8. Janssen Global Services
		18.9. Takeda Pharmaceutical Company Limited
		18.10. Merck & Co., Inc.
	19. Assumptions & Acronyms Used
	20. Research Methodology
Recommendations

Healthcare

Cataract Surgery Device Market

March 2024

REP-GB-635

324 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Post-Operative Cataract Surgery Inflammation Treatment Market

Schedule a Call